Deflazacort induced stronger immunosuppression than expected

González-Castañeda, Rocío E.; Castellanos-Alvarado, E.A.; Flores-Márquez, María Rosa; González-Pérez, Óscar; Luquı́n, Sonia; Garcı́a-Estrada, Joaquı́n; Ramos-Remus, César

doi:10.1007/s10067-006-0223-4

Cited by 9 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been shown by several groups that the anti-inflammatory effects of DEF are comparable to those of commonly used steroids, but with fewer effects on bone mineral content [14]. Moreover, research on animals has proven that DEF produces less neuronal damage than prednisone at an equivalent dosage, but that it generates a greater immunosuppressant effect [16].…”

Section: Discussionmentioning

confidence: 99%

Complete remission of non-HIV collapsing glomerulopathy with deflazacort and lisinopril in an adult patient

et al. 2010

View full text Add to dashboard Cite

Collapsing glomerulopathy is a form of focal segmental glomerulosclerosis that is usually associated with HIV-1 infection, and is characterized by its poor prognosis and almost inevitable progression to end-stage renal disease. Its pathological features include collapsed glomeruli, podocyte hypertrophy and hyperplasia, and pseudocrescents. This case report shows the evolution of a 58-year-old patient with non-HIV idiopathic collapsing glomerulopathy who presented with severe nephrotic syndrome and renal insufficiency and was treated with lisinopril and deflazacort, a synthetic corticosteroid that has shown fewer cosmetic effects and glucose and bone metabolism complications than prednisone. The patient responded with full recovery of renal function and normal range of protein excreted in urine after less than two years of treatment. The patient has not suffered a recurrence of his nephrotic syndrome after three years of steroid withdrawal. There is no proven therapy for collapsing glomerulopathy, and this case highlights an alternative for treating this disease with few secondary effects.

show abstract

Section: Discussionmentioning

confidence: 99%

Complete remission of non-HIV collapsing glomerulopathy with deflazacort and lisinopril in an adult patient

et al. 2010

View full text Add to dashboard Cite

show abstract

“…The drug has been prescribed for treatment of rheumatoid arthritis, asthma and other conditions (Biggar et al, 2006;Angelini, 2007;Ferraris et al, 2007), and is a corticosteroid with a lower risk of side effects than other available steroids (Biggar et al, 2006;Angelini, 2007;Ferraris et al, 2007;Gonzalez-Castañeda et al, 2007).…”

Section: Introductionmentioning

confidence: 99%

Spectrophotometric and HPLC determination of deflazacort in pharmaceutical dosage forms

Scremin

Piazzon

Silva

et al. 2010

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

(DFZ) is a glucocorticoid used as an anti-inflammatory and immunosuppressant drug. No official methods are available for DFZ determination in pharmaceutical formulations. The objective of this study was to develop, validate and compare spectrophotometric (UV and colorimetric) and highperformance liquid chromatography (HPLC) methods, for the quantitative determination of DFZ in tablets and oral suspension. For the UV method, ethanol was used as the solvent, with detection at 244 nm. The colorimetric method was based on the redox reaction with blue tetrazolium in alkaline medium, with detection at 524 nm. The method by HPLC was carried out using a C 18 column, mobile phase consisting of acetonitrile:water (80:20, v/v) with a flow rate of 1.0 mL min -1 and detection at 244 nm. The methods proved linear (r > 0.999), precise (RSD < 5%) and accurate (recovery > 97%). Statistical analysis of the results indicated that the UV and HPLC methods were statistically equivalent, while the values obtained for the colorimetric method differed significantly from the other methods. O deflazacorte (DFZ) é um fármaco glicocorticóide usado como antiinflamatório e imunossupressor. Métodos oficiais não estão disponíveis para a determinação de DFZ em formas farmacêuticas. Este estudo teve como objetivo desenvolver, validar e comparar métodos por espectrofotometria (UV e colorimetria) e cromatografia líquida de alta eficiência (CLAE), na determinação quantitativa de DFZ em comprimidos e suspensão oral. O método por UV utilizou etanol como solvente, com detecção em 244 nm. O método colorimétrico foi baseado na reação de redução com azul de tetrazólio em meio alcalino, com detecção em 524 nm. O método por CLAE utilizou coluna C 18 ; fase móvel constituída de acetonitrila:água (80:20, v/v), com fluxo de 1,0 mL min -1 e detecção em 244 nm. Os métodos foram lineares (r > 0,999); precisos (RSD < 5 %), e exatos (recuperação > 97%). As análises estatísticas dos resultados obtidos indicaram que os métodos por UV e por CLAE foram estatisticamente equivalentes, enquanto os valores obtidos para o método colorimétrico diferiram significativamente dos demais métodos.Unitermos: Deflazacorte/determinação quantitativa. Cromatografia líquida de alta eficiência/análise quantitativa. Espectrofotometria/análise quantitativa. Medicamentos/análise quantitativa.

show abstract

Deflazacort: A glucocorticoid with few metabolic adverse effects but important immunosuppressive activity

et al. 2007

View full text Add to dashboard Cite

Deflazacort (DFZ) is a synthetic glucocorticoid that has few adverse effects on glucose and calcium metabolism and fewer deleterious effects on the neuronal population. Therefore, it may have a crucial role in the treatment of patients with autoimmune disorders associated with central nervous system or metabolic affectations. To date, the pharmacologic safety profile of DFZ is considered similar to that of other glucocorticoids. Nevertheless, cumulative clinical and laboratory evidence suggests that DFZ has, in fact, greater immunosuppressive activity than was previously thought. Therefore, it is possible that DFZ increases the risk of acquiring opportunistic infection compared with other synthetic glucocorticoids. Additional pharmacologic studies are needed to fully establish the immunosuppressive potency of DFZ and, consequently, to determine the appropriate ratio of bioequivalence in humans.

show abstract

Deflazacort induced stronger immunosuppression than expected

Cited by 9 publications

References 17 publications

Complete remission of non-HIV collapsing glomerulopathy with deflazacort and lisinopril in an adult patient

Complete remission of non-HIV collapsing glomerulopathy with deflazacort and lisinopril in an adult patient

Spectrophotometric and HPLC determination of deflazacort in pharmaceutical dosage forms

Deflazacort: A glucocorticoid with few metabolic adverse effects but important immunosuppressive activity

Contact Info

Product

Resources

About